Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012–2013
Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)–diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL...
Saved in:
Published in | Clinical infectious diseases Vol. 63; no. 7; pp. 976 - 983 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)–diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012–2013. Results. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012–2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Conclusions. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression. |
---|---|
AbstractList | Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care. Methods. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013. Results. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Conclusions. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care. Using data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013. Of 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential. Two-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression. BACKGROUNDWe examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed persons in care.METHODSUsing data from the National HIV Surveillance System from 17 jurisdictions with complete reporting of VL test results, we determined the percentage of persons in HIV care who achieved durable viral suppression (all VL results <200 copies/mL) and examined viremia copy-years and time spent above VL levels that increase the risk of HIV transmission during 2012-2013.RESULTSOf 265 264 persons in HIV care in 2011, 238 641 had at least 2 VLs in 2012-2013. The median number of VLs per individual during the 2-year period was 5. Approximately 62% had durable viral suppression. The remaining 38% had high VL burden (geometric mean of viremia copy-years, 7261) and spent an average of 438 days, 316 days, and 215 days (60%, 43.2%, and 29.5% of the 2-year period) above 200, 1500, and 10 000 copies/mL. Women, blacks/African Americans, Hispanics/Latinos, persons with HIV infection attributed to transmission other than male-to-male sexual contact, younger age groups, and persons with gaps in care had higher viral burden and transmission risk potential.CONCLUSIONSTwo-thirds of persons in HIV care had durable viral suppression during a 2-year period. One-third had high VL burden and spent substantial time above VL levels with increased risk of onward transmission. More intervention efforts are needed to improve retention in care and medication adherence so that more persons in HIV care achieve durable viral suppression. |
Author | Marks, Gary Mugavero, Michael J. Crepaz, Nicole Espinoza, Lorena Tang, Tian Hall, H. Irene |
Author_xml | – sequence: 1 givenname: Nicole surname: Crepaz fullname: Crepaz, Nicole – sequence: 2 givenname: Tian surname: Tang fullname: Tang, Tian – sequence: 3 givenname: Gary surname: Marks fullname: Marks, Gary – sequence: 4 givenname: Michael J. surname: Mugavero fullname: Mugavero, Michael J. – sequence: 5 givenname: Lorena surname: Espinoza fullname: Espinoza, Lorena – sequence: 6 givenname: H. Irene surname: Hall fullname: Hall, H. Irene |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27358354$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk1v1DAQhi1URNuFC3eQJS4IEfDEduxwQKpaoCtVoqIfHC3H8W69ZO3FdkDc-h_4h_wSvEopHycO1ljzPn41M559tOODtwg9BPICSEtfGteX85WBvIP2gFNRNbyFnXInXFZMUrmL9lNaEQIgCb-HdmtBuaSc7aHrozHqbrD40kU94LNxs4k2JRc81r7H51H7tHZT4oNLn_BpyNZnV9iDdfBLfGpjCj7hjy5f4SOnlz4k2-Pj-SWe-4U1ubx8hS-8yyV7lnW26TmuCdQ_rr-XQO-juws9JPvgJs7Qxds354fH1cn7d_PDg5PKsAZyJaBhdWOZ7CXXtqO0IaSDVogFCEEoSAqCGy1MxwihnWam67nujRXAhNGEztDryXczdmtbBJ9Lw2oT3VrHbypop_5WvLtSy_BFcVJDQ7cGT28MYvg82pRVmYuxw6C9DWNSIGvRAqsp_Q8UWkZLnaygT_5BV2GMvkxia8gokKb0NkPPJsrEkFK0i9u6gajtDqiyA2ragQI__rPTW_TXpxfg0QSsUg7xt95QUReA_gQwgbjj |
CitedBy_id | crossref_primary_10_1080_08964289_2020_1809336 crossref_primary_10_1097_QAI_0000000000002360 crossref_primary_10_1080_09540121_2018_1545989 crossref_primary_10_1093_ofid_ofae087 crossref_primary_10_1155_2020_9247451 crossref_primary_10_1177_22799036231182031 crossref_primary_10_7448_IAS_19_1_21348 crossref_primary_10_1007_s40615_021_01227_w crossref_primary_10_1093_infdis_jiab021 crossref_primary_10_1093_cid_ciz276 crossref_primary_10_1080_09540121_2017_1417535 crossref_primary_10_1097_QAI_0000000000003178 crossref_primary_10_1002_jia2_26162 crossref_primary_10_1089_apc_2021_0137 crossref_primary_10_1089_apc_2018_0004 crossref_primary_10_1097_QAI_0000000000003045 crossref_primary_10_1016_j_drugalcdep_2019_107670 crossref_primary_10_1007_s10903_018_0753_2 crossref_primary_10_1093_cid_cix940 crossref_primary_10_1016_j_cct_2020_106097 crossref_primary_10_1080_09540121_2020_1771264 crossref_primary_10_1093_ofid_ofz203 crossref_primary_10_1097_QAD_0000000000001660 crossref_primary_10_1007_s10461_019_02734_y crossref_primary_10_1007_s10461_019_02650_1 crossref_primary_10_1080_09540121_2020_1826396 crossref_primary_10_1093_pm_pnx057 crossref_primary_10_1097_QAI_0000000000001779 crossref_primary_10_1186_s12981_024_00626_3 crossref_primary_10_1007_s10461_019_02644_z crossref_primary_10_3390_ijerph18158031 crossref_primary_10_1177_09564624211002403 crossref_primary_10_3389_fgene_2018_00720 crossref_primary_10_1097_OLQ_0000000000000776 crossref_primary_10_1136_bmjopen_2017_018533 crossref_primary_10_1016_S0140_6736_21_00396_2 crossref_primary_10_1007_s10461_019_02474_z crossref_primary_10_1007_s10461_021_03157_4 crossref_primary_10_1371_journal_pone_0244376 crossref_primary_10_1186_s12981_021_00400_9 crossref_primary_10_1007_s10461_024_04275_5 crossref_primary_10_1007_s10461_021_03342_5 crossref_primary_10_1097_QAI_0000000000002056 crossref_primary_10_1007_s11606_024_08847_y crossref_primary_10_3390_ijerph18084170 crossref_primary_10_1177_0033354918772057 crossref_primary_10_1136_sextrans_2017_053178 crossref_primary_10_1093_cid_cix212 crossref_primary_10_1097_QAI_0000000000001877 crossref_primary_10_1097_QAI_0000000000002848 crossref_primary_10_1007_s10865_020_00186_7 crossref_primary_10_1080_13607863_2022_2084504 crossref_primary_10_1093_tbm_ibaa109 crossref_primary_10_1007_s10461_019_02627_0 crossref_primary_10_1016_j_ptdy_2020_03_017 crossref_primary_10_1080_09540121_2022_2080800 crossref_primary_10_1097_MD_0000000000026285 crossref_primary_10_1080_25787489_2020_1735816 crossref_primary_10_1007_s10461_020_03153_0 crossref_primary_10_1007_s10461_019_02578_6 crossref_primary_10_1007_s10461_020_02811_7 crossref_primary_10_1007_s10461_022_03694_6 crossref_primary_10_1177_2150132720984429 crossref_primary_10_1177_09564624211046516 crossref_primary_10_1186_s12879_017_2550_2 crossref_primary_10_1007_s10461_020_02778_5 crossref_primary_10_1016_j_alcohol_2021_04_003 crossref_primary_10_1089_apc_2021_0067 crossref_primary_10_1007_s11121_019_01013_5 crossref_primary_10_1097_QAI_0000000000002277 crossref_primary_10_1097_QAI_0000000000003128 crossref_primary_10_1097_QAI_0000000000003129 crossref_primary_10_1001_jamainternmed_2017_2158 crossref_primary_10_1186_s12889_020_8442_1 crossref_primary_10_1080_08870446_2022_2122462 crossref_primary_10_1007_s10461_019_02399_7 crossref_primary_10_1097_QAI_0000000000002308 crossref_primary_10_1136_bmjopen_2023_077676 crossref_primary_10_1097_QAD_0000000000001597 crossref_primary_10_1001_jama_2018_8431 crossref_primary_10_1097_QAI_0000000000003237 crossref_primary_10_1111_jrh_12384 crossref_primary_10_1186_s12889_020_10088_7 crossref_primary_10_1080_10826084_2021_1884722 crossref_primary_10_1080_09540121_2023_2206096 crossref_primary_10_1080_09540121_2018_1510099 crossref_primary_10_1097_QAD_0000000000001914 crossref_primary_10_1097_QAI_0000000000002933 crossref_primary_10_15585_mmwr_mm6704a2 crossref_primary_10_1177_2325958219826612 crossref_primary_10_1097_QAD_0000000000001921 crossref_primary_10_1097_QAD_0000000000002579 crossref_primary_10_1097_QAD_0000000000002612 crossref_primary_10_1007_s10461_020_02803_7 crossref_primary_10_1007_s10461_022_03958_1 crossref_primary_10_1371_journal_pmed_1002667 crossref_primary_10_1097_QAI_0000000000002138 crossref_primary_10_1089_apc_2020_0074 crossref_primary_10_1097_QAI_0000000000002019 |
Cites_doi | 10.1056/NEJMoa1105243 10.1177/2325957415613442 10.1001/jamainternmed.2015.4095 10.1097/QAD.0000000000000108 10.1093/cid/cir526 10.7326/0003-4819-157-5-201209040-00005 10.1086/599313 10.1371/journal.pone.0029679 10.1097/QAD.0000000000000057 10.1097/QAI.0b013e3182945bc7 10.1097/QAI.0000000000001036 10.1001/jama.2014.7999 10.1097/QAD.0000000000000640 10.1097/QAD.0000000000000879 10.1056/NEJM200003303421303 10.1093/cid/ciu722 |
ContentType | Journal Article |
Copyright | Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. Copyright Oxford University Press, UK Oct 1, 2016 |
Copyright_xml | – notice: Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America – notice: Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. – notice: Copyright Oxford University Press, UK Oct 1, 2016 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 7U2 5PM |
DOI | 10.1093/cid/ciw418 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic Safety Science and Risk PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic Safety Science and Risk |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-6591 |
EndPage | 983 |
ExternalDocumentID | 4198442751 10_1093_cid_ciw418 27358354 26372835 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article Feature |
GeographicLocations | United States--US USA |
GeographicLocations_xml | – name: United States--US – name: USA |
GrantInformation_xml | – fundername: Intramural CDC HHS grantid: CC999999 |
GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1KJ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABJS AABMN AABZA AACGO AACZT AAESY AAIYJ AAJKP AAJQQ AAMVS AANCE AANRK AAOGV AAPNW AAPQZ AAPXW AAQQT AAUQX AAVAP ABBHK ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABPLY ABPTD ABQLI ABSAR ABTLG ABWST ABXSQ ABZBJ ACGFO ACGFS ACIMA ACPRK ACUFI ACUTO ACYHN ADBBV ADEIU ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADULT ADVEK ADYVW ADZLD ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AIKOY AIMBJ AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASMCH AWCFO AXUDD AZQFJ BAWUL BAYMD BCRHZ BEYMZ BGYMP BHONS BTRTY BVRKM BYORX C45 CASEJ CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DNJUQ DOOOF DPORF DPPUQ DU5 DWIUU D~K E3Z EBS EE~ EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HW0 HZ~ IOX J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- NVLIB O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ZA5 ~91 ~S- AARHZ AAUAY ABNHQ ABQNK ABXVV ADACV ADQBN ATGXG CGR CUY CVF ECM EIF H13 IPSME NPM AASNB AAYXX CITATION 7QL 7T2 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N P64 7X8 7U2 5PM |
ID | FETCH-LOGICAL-c461t-716426e48d85aeb33600b1977f17703183175ca7cb4003ba4cbd5adce7147ca03 |
ISSN | 1058-4838 |
IngestDate | Tue Sep 17 21:17:12 EDT 2024 Fri Oct 25 06:25:56 EDT 2024 Fri Oct 25 07:37:01 EDT 2024 Thu Oct 10 18:48:10 EDT 2024 Thu Sep 12 19:34:10 EDT 2024 Wed Oct 16 01:00:00 EDT 2024 Fri Feb 02 07:29:58 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | HIV-diagnosed persons disparity durable viral suppression viral burden HIV transmission risk |
Language | English |
License | Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c461t-716426e48d85aeb33600b1977f17703183175ca7cb4003ba4cbd5adce7147ca03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/cid/article-pdf/63/7/976/7081320/ciw418.pdf |
PMID | 27358354 |
PQID | 1824310618 |
PQPubID | 48300 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5021630 proquest_miscellaneous_1827914233 proquest_miscellaneous_1819430034 proquest_journals_1824310618 crossref_primary_10_1093_cid_ciw418 pubmed_primary_27358354 jstor_primary_26372835 |
PublicationCentury | 2000 |
PublicationDate | 2016-10-01 |
PublicationDateYYYYMMDD | 2016-10-01 |
PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | Clinical infectious diseases |
PublicationTitleAlternate | Clin Infect Dis |
PublicationYear | 2016 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | 25225233 - Clin Infect Dis. 2015 Jan 1;60(1):117-25 26322677 - JAMA Intern Med. 2015 Oct;175(10):1650-9 26527218 - J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3-S34 25038358 - JAMA. 2014 Jul 23-30;312(4):390-409 10738050 - N Engl J Med. 2000 Mar 30;342(13):921-9 25768835 - AIDS. 2015 May 15;29(8):947-54 24983541 - AIDS. 2014 Mar 13;28(5):633-56 26372483 - AIDS. 2015 Nov 28;29(18):2371-83 22944874 - Ann Intern Med. 2012 Sep 4;157(5):325-35 21890751 - Clin Infect Dis. 2011 Nov;53(9):927-35 22291892 - PLoS One. 2012;7(1):e29679 25426654 - MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1113-7 27105049 - J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):205-12 19476437 - J Infect Dis. 2009 Jul 1;200(1):79-87 23572013 - J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):299-306 24056066 - AIDS. 2014 Jan 28;28(3):407-15 21767103 - N Engl J Med. 2011 Aug 11;365(6):493-505 Centers for Disease Control and Prevention (2016091209330666000_63.7.976.12) 2014; 63 2016091209330666000_63.7.976.18 2016091209330666000_63.7.976.19 2016091209330666000_63.7.976.16 2016091209330666000_63.7.976.17 2016091209330666000_63.7.976.2 2016091209330666000_63.7.976.14 2016091209330666000_63.7.976.1 2016091209330666000_63.7.976.15 2016091209330666000_63.7.976.23 2016091209330666000_63.7.976.13 2016091209330666000_63.7.976.10 2016091209330666000_63.7.976.21 2016091209330666000_63.7.976.11 2016091209330666000_63.7.976.22 2016091209330666000_63.7.976.20 2016091209330666000_63.7.976.9 2016091209330666000_63.7.976.8 2016091209330666000_63.7.976.7 2016091209330666000_63.7.976.6 2016091209330666000_63.7.976.5 2016091209330666000_63.7.976.4 2016091209330666000_63.7.976.3 |
References_xml | – ident: 2016091209330666000_63.7.976.1 – ident: 2016091209330666000_63.7.976.2 – ident: 2016091209330666000_63.7.976.3 doi: 10.1056/NEJMoa1105243 – ident: 2016091209330666000_63.7.976.18 doi: 10.1177/2325957415613442 – ident: 2016091209330666000_63.7.976.22 doi: 10.1001/jamainternmed.2015.4095 – ident: 2016091209330666000_63.7.976.16 doi: 10.1097/QAD.0000000000000108 – ident: 2016091209330666000_63.7.976.4 doi: 10.1093/cid/cir526 – volume: 63 start-page: 1 year: 2014 ident: 2016091209330666000_63.7.976.12 article-title: Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011 publication-title: MMWR Morb Mortal Wkly Rep contributor: fullname: Centers for Disease Control and Prevention – ident: 2016091209330666000_63.7.976.9 doi: 10.7326/0003-4819-157-5-201209040-00005 – ident: 2016091209330666000_63.7.976.6 doi: 10.1086/599313 – ident: 2016091209330666000_63.7.976.14 doi: 10.1371/journal.pone.0029679 – ident: 2016091209330666000_63.7.976.17 doi: 10.1097/QAD.0000000000000057 – ident: 2016091209330666000_63.7.976.10 doi: 10.1097/QAI.0b013e3182945bc7 – ident: 2016091209330666000_63.7.976.11 – ident: 2016091209330666000_63.7.976.13 doi: 10.1097/QAI.0000000000001036 – ident: 2016091209330666000_63.7.976.19 doi: 10.1001/jama.2014.7999 – ident: 2016091209330666000_63.7.976.15 doi: 10.1097/QAD.0000000000000640 – ident: 2016091209330666000_63.7.976.20 doi: 10.1097/QAD.0000000000000879 – ident: 2016091209330666000_63.7.976.5 doi: 10.1056/NEJM200003303421303 – ident: 2016091209330666000_63.7.976.7 – ident: 2016091209330666000_63.7.976.21 – ident: 2016091209330666000_63.7.976.23 – ident: 2016091209330666000_63.7.976.8 doi: 10.1093/cid/ciu722 |
SSID | ssj0011805 |
Score | 2.5652375 |
Snippet | Background. We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus... We examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus (HIV)-diagnosed... BACKGROUNDWe examined durable viral suppression, cumulative viral load (VL) burden, and transmission risk potential among human immunodeficiency virus... |
SourceID | pubmedcentral proquest crossref pubmed jstor |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 976 |
SubjectTerms | Adolescent Adult Anti-HIV Agents - therapeutic use Disease transmission Female HIV HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - transmission HIV Infections - virology HIV-1 HIV/AIDS Human immunodeficiency virus Humans Lentivirus Male Medical diagnosis Middle Aged Retroviridae Risk Risk factors Sustained Virologic Response United States - epidemiology Viral Load Young Adult |
Title | Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012–2013 |
URI | https://www.jstor.org/stable/26372835 https://www.ncbi.nlm.nih.gov/pubmed/27358354 https://www.proquest.com/docview/1824310618 https://search.proquest.com/docview/1819430034 https://search.proquest.com/docview/1827914233 https://pubmed.ncbi.nlm.nih.gov/PMC5021630 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELWWIiEuiK9CoCAjOBIax46TcEMtaAsqqtAW9RbZ3qTdA9lqmwipB678bWZsx5uFgoBLtIqdZOX3PDO2n8eEvFBSg9MpoacZwWNRSBXrotHxvBTKzBvwSHZC__CjnB6L9yfZyWTyfaRa6jv9ylxeua_kf1CFe4Ar7pL9B2TDS-EG_AZ84QoIw_WvMN7vV3bn0-cFbrPHAzqdqtUJjK0bAhjtjU8oIT9adigOQlTsGUNHNtxGCWx3BsbPiu4gAJ3CkPDAi7Ss8GMjMEVQwJ-n0EZuf2dIdDBsshwEXv3FsP4TAve9Fbi_y0DBwKqZn7aejdiK24jcvL0aaZX7UwU4LUeSf7-y5acumAwiOPA8g7nNY5m587oGe-wNnuNdPjKupTsp5hej7xJiGQuyWXwVzqCP8D__YssgUstwnmvt-oIgcSi6Rq6nYLFQG7h_8CEsR7EiyYbctiXfhU_tug9hLmn_6EZg47StV41afhbfjqKZ2W1yyw9D6BvHqTtkUrd3yY1DL7S4R755alFLLTqiFgVq0TG1KFKLBmpRSy3qqUWRWjRQiwK1aKDWa-qIRR2xXtJAq_vk-N3b2d409kd1xEZI1sU46k5lLYp5kalacw5xtGYwtmhYnlu_AWGqUbnR4DO4VsLoeaagDXImcqMSvk222mVbPyS0Zqws6lolZdoIMddKpkVi8lpmDUedVkSeD-1cnbuMLJVTUvAKj6F2wERk20IQqqSS55hbMCI7AyaV78oXFQyyIZCG0BaeexaKoRlx9Uy1NXQYqMPwqIKEiz_VAfYwGKHwiDxwMK__gOdJRPINAoQKmOh9s6RdnNmE7xkE4pInj377zsfk5rp_7ZCtbtXXTyBY7vRTS-QfPAXBDA |
link.rule.ids | 230,315,783,787,888,27938,27939 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Durable+Viral+Suppression+and+Transmission+Risk+Potential+Among+Persons+With+Diagnosed+HIV+Infection%3A+United+States%2C+2012-2013&rft.jtitle=Clinical+infectious+diseases&rft.au=Crepaz%2C+Nicole&rft.au=Tang%2C+Tian&rft.au=Marks%2C+Gary&rft.au=Mugavero%2C+Michael+J&rft.date=2016-10-01&rft.eissn=1537-6591&rft.volume=63&rft.issue=7&rft.spage=976&rft_id=info:doi/10.1093%2Fcid%2Fciw418&rft_id=info%3Apmid%2F27358354&rft.externalDocID=27358354 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |